2020-12-02

Camurus announces that Braeburn receives Complete Response Letter for Brixadi for opioid use disorder in the US

Camurus AB today announced that Camurus licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for Brixadi.

Read the full press release: https://www.camurus.com/

Camurus' Interim Report Second Quarter 2020

”For the fourth quarter in a row, we saw Buvidal® sales growth of more than 50%”

2020-06-24

Positive results from Phase 2 study

Positive results from Phase 2 study of once-weekly FluidCrystal® formulation of setmelanotide in healthy volunteers…

2020-06-23

Camurus raises full year 2020 revenue guidance

The improvements are driven by increasing market shares of Buvidal® for treatment of opioid dependence in Europe and…

2020-05-07

Camurus Interim Report January-March 2020

”The number of patients treated with Buvidal® increased by 90 percent in the quarter”

2020-04-08

Camurus Annual Report for 2019

Camurus Annual Report for 2019 is now available at the company´s website.